Intellectual Property
Escape has acquired four stem cell related inventions from Stanford University, Stanford, CA. This intellectual property has served as the foundation for Escape's proprietary universal stem cell platform technology. Escape will extend its intellectual property position by successfully engineering this gatekeeper platform technology into all stem cell types susceptible to donor rejection, a phenomenon seriously limiting successful commercialization of adult-derived and embryonic stem cells. Initially, Escape will focus on developing allogeneic somatic and stem cell-based products for the treatment of type I diabetes, graft-versus-host disease, and partial thickness wounds. For indications such as leukemia, acute myocardial infarction, acute spinal cord injury, Escape will pursue strategic alliances to accelerate development and expand the scope of the technology. Escape anticipates completing preclinical trials within 12-18 months of closing and will then transition to GMP manufacturing, submission of IND applications, and entry into FDA Phase I clinical trials.
